A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Trial Profile

A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Apr 2017 Results of pooled analysis (n=185) for development of semimechanistic population PK/PD model for understanding neutropenia associated with palbociclib using patient data from NCT00141297, NCT00420056, NCT00721409 trials, published in the Journal of Clinical Pharmacology
    • 27 Oct 2015 Trial focus changed from PK+AR to PK+AR+TU. Endpoints has been added as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top